The CAVIAR trial evaluated safety and efficacy of the PCSK9 inhibitor alirocumab for prevention of cardiac allograft vasculopathy after heart transplantation. Once-weekly subcutaneous semaglutide 2.4 ...

Simultaneous or rapid initiation of evidence-based therapies significantly improves quality of life and outcomes in patients with heart failure with moderately reduced or preserved ejection fraction, ...

Optimize time management with these 6 non-medication strategies for ADHD. Discover effective hacks like timers, body doubling ...

Cardiovascular disease causes one-third of deaths worldwide and represents an urgent threat to global health. The scientific, clinical, pharmacological and public health communities have coordinated ...

Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...

Dec. 27, 2025 Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and how that risk might be reduced. They found that the vaccines ...

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

Background Depression is a risk factor and complication of coronary artery disease (CAD) that is associated with poor ...